tetano
Editor, Senior Moderator
J Virol
. 2022 Sep 15;e0100622.
doi: 10.1128/jvi.01006-22. Online ahead of print.
Respiratory Vaccination with Hemagglutinin Nanoliposomes Protects Mice from Homologous and Heterologous Strains of Influenza Virus
Zachary R Sia[SUP] 1 [/SUP], Kevin Chiem[SUP] 2 3 [/SUP], Wei-Chiao Huang[SUP] 1 [/SUP], Amal Seffouh[SUP] 4 [/SUP], Amir Teimouri Dereshgi[SUP] 5 6 [/SUP], Tara Hogan[SUP] 5 6 [/SUP], Joaquin Ortega[SUP] 4 [/SUP], Bruce A Davidson[SUP] 5 6 [/SUP], Luis Martinez-Sobrido[SUP] 2 3 [/SUP], Jonathan F Lovell[SUP] 1 [/SUP]
Affiliations
Abstract
Intranasal vaccination offers the potential advantage of needle-free prevention of respiratory pathogens such as influenza viruses with induction of mucosal immune responses. Optimal design of adjuvants and antigen delivery vehicles for intranasal delivery has not yet been well established. Here, we report that an adjuvant-containing nanoliposome antigen display system that converts soluble influenza hemagglutinin antigens into nanoparticles is effective for intranasal immunization. Intranasal delivery of nanoliposomes in mice delivers the particles to resident immune cells in the respiratory tract, inducing a mucosal response in the respiratory system as evidenced by nasal and lung localized IgA antibody production, while also producing systemic IgG antibodies. Intranasal vaccination with nanoliposome particles decorated with nanogram doses of hemagglutinin protected mice from homologous and heterologous H3N2 and H1N1 influenza virus challenge. IMPORTANCE A self-assembling influenza virus vaccine platform that seamlessly converts soluble antigens into nanoparticles is demonstrated with various H1N1 and H3N2 influenza antigens to protect mice against influenza virus challenge following intranasal vaccination. Mucosal immune responses following liposome delivery to lung antigen-presenting cells are demonstrated.
Keywords: immunization; influenza; intranasal; liposomes; subunit vaccine.
. 2022 Sep 15;e0100622.
doi: 10.1128/jvi.01006-22. Online ahead of print.
Respiratory Vaccination with Hemagglutinin Nanoliposomes Protects Mice from Homologous and Heterologous Strains of Influenza Virus
Zachary R Sia[SUP] 1 [/SUP], Kevin Chiem[SUP] 2 3 [/SUP], Wei-Chiao Huang[SUP] 1 [/SUP], Amal Seffouh[SUP] 4 [/SUP], Amir Teimouri Dereshgi[SUP] 5 6 [/SUP], Tara Hogan[SUP] 5 6 [/SUP], Joaquin Ortega[SUP] 4 [/SUP], Bruce A Davidson[SUP] 5 6 [/SUP], Luis Martinez-Sobrido[SUP] 2 3 [/SUP], Jonathan F Lovell[SUP] 1 [/SUP]
Affiliations
- PMID: 36106872
- DOI: 10.1128/jvi.01006-22
Abstract
Intranasal vaccination offers the potential advantage of needle-free prevention of respiratory pathogens such as influenza viruses with induction of mucosal immune responses. Optimal design of adjuvants and antigen delivery vehicles for intranasal delivery has not yet been well established. Here, we report that an adjuvant-containing nanoliposome antigen display system that converts soluble influenza hemagglutinin antigens into nanoparticles is effective for intranasal immunization. Intranasal delivery of nanoliposomes in mice delivers the particles to resident immune cells in the respiratory tract, inducing a mucosal response in the respiratory system as evidenced by nasal and lung localized IgA antibody production, while also producing systemic IgG antibodies. Intranasal vaccination with nanoliposome particles decorated with nanogram doses of hemagglutinin protected mice from homologous and heterologous H3N2 and H1N1 influenza virus challenge. IMPORTANCE A self-assembling influenza virus vaccine platform that seamlessly converts soluble antigens into nanoparticles is demonstrated with various H1N1 and H3N2 influenza antigens to protect mice against influenza virus challenge following intranasal vaccination. Mucosal immune responses following liposome delivery to lung antigen-presenting cells are demonstrated.
Keywords: immunization; influenza; intranasal; liposomes; subunit vaccine.